Vaxcyte, Inc. (NASDAQ:PCVX) Receives $112.25 Consensus Target Price from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been assigned an average rating of “Buy” from the seven analysts that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $131.83.

PCVX has been the subject of a number of research analyst reports. BTIG Research increased their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Needham & Company LLC increased their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Leerink Partners increased their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group increased their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Thursday, June 20th.

Insiders Place Their Bets

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the sale, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Vaxcyte news, COO Jim Wassil sold 10,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $111.93, for a total transaction of $1,119,300.00. Following the sale, the chief operating officer now directly owns 207,503 shares in the company, valued at approximately $23,225,810.79. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total transaction of $538,350.00. Following the sale, the senior vice president now owns 12,723 shares in the company, valued at $1,369,885.41. The disclosure for this sale can be found here. Insiders have sold a total of 85,283 shares of company stock worth $7,271,218 in the last ninety days. 3.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of PCVX. Darwin Global Management Ltd. raised its holdings in shares of Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after purchasing an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Norges Bank acquired a new stake in shares of Vaxcyte in the 4th quarter valued at $57,494,000. Capital Research Global Investors raised its holdings in shares of Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after purchasing an additional 700,414 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 9.9% in the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Price Performance

Vaxcyte stock opened at $115.28 on Tuesday. The firm has a 50 day simple moving average of $82.56 and a 200-day simple moving average of $73.83. Vaxcyte has a 1-year low of $44.20 and a 1-year high of $119.27. The stock has a market cap of $12.54 billion, a price-to-earnings ratio of -26.93 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. Equities analysts expect that Vaxcyte will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.